Corporate Office & Central Laboratory:

6/3, Manoramaganj, Indore - 452 001 (MP) INDIA Tel: +91 731 4243850 - 88 Fax: +91 731 2490593

Email: indore@choksilab.com Website: <u>www.choksilab.com</u> CIN: L85195MP1993PLC007471



To, Date: 13.02.2023

Bombay Stock Exchange Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai- 400 001.

Subject: Outcome of Board Meeting held on 13th February, 2023.

Ref: Scrip Code: 526546, ISIN: INE493D01013.

Meeting started at 03.00 P.M. and concluded at 04.00 P.M.

Dear Sir/Madam,

Pursuant to regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, We Wish to inform you that following business were transacted at the meeting of the Board of Directors of the Company held on Monday the day of 13th February, 2023 at the registered office of the Company situated at Survey No 9/1, Near Balaji Tulsiyana Industrial Estate, Gram Kumedi, Indore, 452010 MP;

- 1. The Board have approved and taken on record, inter alia, unaudited standalone Financial Results of the Company for the guarter and nine months ended on 31st December, 2022.
- 2. Approved the appointment of Ms. Surabhi Agrawal, Practicing Company Secretary for conducting Secretarial audit and compliance Report for the Financial Year 2022-23;

A Copy of results along with Limited review Report of the Statutory Auditors of the Company as required under regulation 33 of the SEBI (LODR) Regulation 2015, is enclosed herewith.

The aforesaid results are also being disseminated on company's website at www.choksilab.com

Thanking You
Yours faithfully
For Choksi Laboratories Limited

For Choksi Kaboratories Ltd

Company Secretary

Yash Gupta

Compliance Officer & Company Secretary

Place: Indore

PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS 212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANI, INDORE (M.P.) 452001

PH. 9827013187, 731-3590283

E-MAIL: caprateekjain@gmail.com



Independent Auditor's Review Report on the unaudited Quarterly and Year to date Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To, The Board of Directors Choksi Laboratories Limited Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited standalone financial results of CHOKSI LABORATORIES LIMITED ("the Company") for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 ("the statement") attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE 2410) "Review of Interim Financial Information Performed by Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS 212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ, INDORE (M.P.) 452001 PH. 9827013187, 731-2520955

E-MAIL: caprateekjain@gmail.com



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in all material respect in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the review and significant findings, including any significant deficiencies in internal control that we identify during our review.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

FOR PRATEEK JAIN AND CO.
CHARTERED ACCOUNTANTS
FRN.0094946

FRN-009494C

Date: 13th February, 2023

Place: Indore

UDIN: 23079214BGZGSF4455

PRATEEK JAIN PROPRIETOR M.NO.079214

CHOKSI LABORATORIES LTD.

Registered Office: Survey No 9/1, Tulsiyana Industrial Park, Kumedi, Indore (MP) 452010

Registered Office : Survey No 9/1, Tulsiyana Industrial Park, Kumedi, Indore (MP) 452010							
Statement of Unaudited Financial Results for the Quarter and 9 Months Ended on 31st December'2022							
							(Rs. In Lakhs)
		Quarter Ended			Nine Month Ended		Year Ended
Sl. No.	PARTICULARS	3 Months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to Date figures for the current period ended	Year to Date figures for the previous period ended	Previous Year ended
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operation	783.58	868.33	736.96	2474.66	1990.42	3004.21
II	Other Income	10.18	1.68	0.36	12.56	9.79	11.96
III	Total Income (I+II)	793.76	870.01	737.32	2487.22	2000.21	3016.17
IV	Expenses	175.10	070.01	131.32	2407.22	2000.21	3010.17
17	(a) Cost of materials consumed	32.75	74.41	48.67	158.19	153.19	198.34
	` /	325.09	346.91	297.38	997.96	886.28	1200.93
	(b) Employee benefits expenses						
	(c) Finance Cost	92.99	87.20		255.40	244.91	320.89
	(d) Depreciation and amortisation expense	136.49	131.18	135.97	407.31	408.15	542.78
	(e) Laboratories Maintainance Expenses	73.11	82.69	57.69	237.16	179.86	249.29
	(f) Power & Fuel Charges	19.18	22.28	17.42	65.11	54.07	69.81
	(g) Other expenses	110.25	108.93	100.68	331.08	298.22	397.43
	Total expenses	789.86	853.60		2452.21	2224.68	2979.47
V	Profit/(Loss) before exceptional items and tax (III-IV)	3.90	16.41	3.90	35.01	(224.47)	36.70
VI	Extraordinary Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	3.90	16.41	3.90	35.01	(224.47)	36.70
VIII	Tax Expenses						
	(a) Current Tax	1.04	2.17	0.00	5.50	0.00	4.94
	(b) Mat Credit Entitlement	(1.04)	(2.17)	0.00	(5.50)	0.00	(4.94)
	(c) Deferred Tax	17.11	10.68	1.04	12.63	(21.27)	16.00
IX	Profit/(Loss) for the period (VII-VIII)	(13.21)	5.73	2.86	22.38	(203.20)	20.70
X	Other Comprehensive Income						
	(a) (i) Items that will not be reclassified to profit & loss	(1.70)	(1.70)	4.50	(5.10)	13.50	(6.83)
	(ii) Income tax relating to items that will not be reclassified to	(=1, 4)	(=1, 0)		(0.120)		(0.00)
	profit & loss	0.44	0.44	(1.17)	1.32	(3.51)	1.77
	(b) (i) Items that will be re-classified to profit & loss		-	-			-
	(ii) Income tax relating to items that will be reclassified to profit & loss		_	-		-	-
XI	Total Comprehensive Income (IX+X)	(14.47)	4.47	6.19	18.60	(193.21)	15.64
XII	Details of Equity Share Capital						
	(a) Paid-up equity share capital	696.52	696.52	696.52	696.52	696.52	696.52
	(b) Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
XIII	Earnings per equity share (for continuing operation)	13.00	20.00	12.00	10.00	12.00	20.00
	(a) Basic	(0.19)	0.08	0.04	0.32	(2.92)	0.30
	(b) Diluted	(0.19)	0.08	0.04	0.32	(2.92)	0.30
XIV	Earnings per equity share (for discontinued operation)	(0.19)	0.06	0.04	0.52	(2.92)	0.30
231 Y	(a) Basic		_	_		_	_
	(b) Diluted		-	-		-	
XV	Earnings per equity share (for discontinued and continuing operation)	-	-	-	-	-	-
	(a) Basic	(0.19)	0.08	0.04	0.32	(2.92)	0.30
	(b) Diluted	(0.19)	0.08	0.04	0.32	(2.92)	0.30
	\-,	(0.17)	0.00	0.01	0.52	(2.72)	0.50

Cont.

Notes to the results: Page - 2

These results have been prepared as per Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 and in accordance with the Indian Accounling Standards (Ind AS) notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules 2015 as amended and other accounting principles generally accepted in India.

- The figures for the quarter and Nine Month ended on 31st December, 2022 are the balancing figures between unaudited figures in respect of the Nine month ended on December 31, 2022 and the published unaudited figures for Half Year ended on September 30, 2022.
- The above Financial Results for the quarter and nine month ended on 31st December 2022 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Monday, 13th February 2023.
- 4 Depreciation on fixed assets is provided on straight line method as per the estimated remaining useful lives of assets.
- The Company has identified "Analysis and Testing" as the single operating segment for the continued operations in the financial statements as per Ind AS 108 "Operating Segments".
- 6 Figures for the previous periods have been regrouped, wherever necessary and minus figures are shown in brackets.
- 7 Revenue from Operations is shown exclusive of GST
- 8 "Other Income" for the quarter and nine month ended on 31 December 2022 includes :- Interest Income Rs. 10.23 Lacs and Foreign Exchange Gain Rs. 2.33 Lacs.
- 9 Earnings per share amount is shown in Rupees.
- 10 For any queries email at compliance_officer@choksilab.com

For and on behalf of the Board of Directors of CHOKSI LABORATORIES LIMITED

Sunil Choksi Managing Director DIN 00155078

Date: 13th February 2022

Place: Indore